SCHAUMBURG, Ill., Sept. 10, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that it has upsized its previously announced registered offering from 4,441,627 to 4,600,000 shares of its common stock and priced the offering at a public offering price of $21.25 per share. Of these shares, the Company has agreed to sell 3,542,470 shares of common stock and selling stockholders have agreed to sell, collectively, 1,057,530 shares of common stock. In addition, the selling shareholders, collectively, intend to grant the underwriters a 30-day option to purchase up to an additional 690,000 shares of common stock, all at the public offering price less the underwriter discount. The offering is expected to close on September 16, 2013, subject to customary closing conditions.
Sagent Pharmaceuticals Announces Upsizing And Pricing Of Offering Of 4,600,000 Shares Of Common Stock
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.